ADA:
Oralin as a Meal Insulin in Treatment of Type-2 Diabetes
RapidMist,
a novel buccal diabetes rapid insulin delivery device.
The
painful nature of injections is a major problem for Type-2 diabetics
failing on oral agents and most patients are reluctant to go on
injections. The alternative to this is the RapidMist, a novel
Diabetes Management System based on a unique
liquid aerosol formulation of oral insulin (Oralin). It allows a
precise insulin dose delivery as fine aerosolized droplets directed in
the mouth and rapidly absorbed through the buccal and oropahrynx
mucosae. In the present study we evaluated the efficacy of the Oralin
versus s.c. injection (0.11u/kg) in controlling post-prandial glucose
in 11 Type-2 diabetic patients after a standard meal challenge. In a
single blind, randomized, crossover study, 11 Type-2 diabetic patients
received Oralin (15 puffs) via the RapidMist device or s.c. injection
(0.11u/kg) followed by a 360 cals Ensure meal, 10 mins after the dose.
The table below shows serum glucose, insulin and C-peptide changes
from the baseline.
Time,
Injection Oral
Injection Oral
Injection Oral
min
Glucose Glucose
Insulin Insulin
C-peptide C-peptide
mg/dl
mg/dl uU/ml
uU/ml ng/ml
ng/ml
0
163 183
47
32 0.52
0.47
15
168 180
67
88 0.55
0.46
60
227 213
74
50 1.01
0.76
120
262
254
71
47 1.44
1.05
240
199
204
70
29 0.92
0.77
We
conclude that the oral insulin absorption and elimination was much
faster when compared to s.c injection (Tmax=88, at 15 min) and
outperformed s.c. injection in terms of glucose and C-peptide lowering
capacity as well as rise in the insulin levels. American
Diabetes Association's 62nd Annual Scientific Sessions
================================
73%
of graduating students have some type of guaranteed student loan. You
can refinance those loans at a much lower rate. Click
here to get more info
[an error occurred while processing this directive]
